THERMO FISHER SCIENTIFIC INC.(TMO)— Stock Profile, AI Score & Financials
Technology · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
THERMO FISHER SCIENTIFIC INC. (TMO) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores TMO at 65.1/100 on a 32-signal composite quality model, placing it at rank #504 of 2,960 stocks — the top 25% of the AI-ranked universe. TMO scores in the top quartile across revenue scale (96.7), balance sheet strength (75.7). Based on the latest XBRL financial filings (Q2 2026), THERMO FISHER SCIENTIFIC INC. reports quarterly revenue of $12.0B, net income of $1.7B, an operating margin of 17.4%. Top institutional holders of TMO by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. TMO trades on the NYSE exchange and files with the SEC under CIK 97745. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TMO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for THERMO FISHER SCIENTIFIC INC. directly from SEC EDGAR.
AI Quality Score
65.1/100
AI Rank
#504
Revenue
$12.0B
Net Income
$1.7B
Free Cash Flow
$1.7B
Operating Margin
17.4%
TMO key financials by period
THERMO FISHER SCIENTIFIC INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$44.6B
$6.7B
17.4%
FY 2024
10-K
$42.9B
$6.3B
17.1%
FY 2023
10-K
$42.9B
$6.0B
16.0%
FY 2022
10-K
$44.9B
$7.0B
18.7%
FY 2021
10-K
$39.2B
$7.7B
25.6%
FY 2020
10-K
$32.2B
—
24.2%
Institutions holding TMO
Institutional investors reporting a position in THERMO FISHER SCIENTIFIC INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 27, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue rose 10% to $11.99B, but only 5% organically — acquisitions (chiefly Clario) contributed 5 points — while GAAP operating margin improved to 17.4% from 16.9%.
Biggest Revenue Drivers
Laboratory Products and Biopharma Services$6,652M+12% YoY
Growth in the research and safety market channel and the clinical research business
Life Sciences Solutions$2,355M+13% YoY
Bioproduction grew $196 million on higher pharma and biotech demand plus the 2025 filtration and separation acquisition
Biggest Revenue Drivers
Total revenue: $11,994M+10% YoY
Laboratory Products and Biopharma Services$6,652M+12% YoY
Growth in the research and safety market channel and the clinical research business
Within Laboratory Products and Biopharma Services
Clinical research$2,396M
Grew $441 million, contributing 7 points of segment reported growth, primarily driven by the impact of the Clario acquisition
Life Sciences Solutions$2,355M+13% YoY
Bioproduction grew $196 million on higher pharma and biotech demand plus the 2025 filtration and separation acquisition
Analytical Instruments$1,799M+7% YoY
Growth across all three businesses, led by electron microscopy (+$55 million)
Specialty Diagnostics$1,188M+6% YoY
Driven by the healthcare market channel (+$36 million) and immunodiagnostics business
Largest Expense Items
Cost of service revenues$3,650M
Rose from $3,207M a year ago as service revenues grew to $5,171M
Cost of product revenues$3,462M
Up from $3,239M; company cites productivity improvements from its PPI Business System
Selling, general and administrative expenses$2,333M
Up from $2,140M, reflecting acquisitions and strategic investments in commercial capabilities
Research and development expenses$364M
Up modestly from $352M
Margins: GAAP operating margin rose 0.5 pt to 17.4% and adjusted margin 0.9 pt to 22.8%, due primarily to strong productivity improvements, offset in part by unfavorable business mix.
Watch Items from the Filing
Reported growth of 10% included 5 points from acquisitions and 1 point currency; organic growth was only 5%.
Clario purchase price totaled $9.10B, adding $5,934M goodwill; cash fell from $9.85B to $4.06B and total debt rose to $42.55B.
Net interest expense nearly doubled to $194M from $107M on higher debt for buybacks, dividends and the Clario acquisition.
Additional restructuring charges of approximately $220 million expected, primarily in the Laboratory Products and Biopharma Services segment.
Remaining performance obligations of $29.70 billion, about 52% expected to be recognized within the next twelve months.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
